Skip to content

Author

A. Caffrey

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Cost-Effectiveness of Sulbactam-durlobactam Compared with Colistin for Treating Carbapenem-Resistant Acinetobacter baumannii Infections in Critical Care Settings in the United States

Although treatment costs were higher, sulbactam-durlobactam has a favorable cost-effectiveness profile as compared with colistin when accounting for the costs of managing acute kidney injury, which is more frequent in colistin-treated patients.

A. Ologunowa, A. Caffrey, S. Cohen et al. · 0 citations
Open access Sep 2026

Effectiveness of 20-valent pneumococcal conjugate vaccine against pneumococcal pneumonia hospitalizations among U.S. adults: Test-Negative Design

The findings support the importance of aligning pneumococcal vaccination strategies with regional serotype distribution to maximize vaccine impact and support the importance of aligning pneumococcal vaccination strategies with regional serotype distribution to maximize vaccine impact.

A. Ologunowa, S. Kogut, V. L. Vrishali et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.